Request Demo
Last update 08 May 2025
Lamivudine/Raltegravir Potassium
Last update 08 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms DUTREBIS, Lamivudine/raltegravir, Raltegravir/3TC + [3] |
Target |
Action inhibitors |
Mechanism HIV-1 integrase inhibitors(HIV integrase inhibitors), RT inhibitors(Viral reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (06 Feb 2015), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC20H21FKN6O5 |
InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N |
CAS Registry871038-72-1 |
View All Structures (2)
Related
1
Clinical Trials associated with Lamivudine/Raltegravir PotassiumNCT02284035
Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.
100 Clinical Results associated with Lamivudine/Raltegravir Potassium
Login to view more data
100 Translational Medicine associated with Lamivudine/Raltegravir Potassium
Login to view more data
100 Patents (Medical) associated with Lamivudine/Raltegravir Potassium
Login to view more data
1
Literatures (Medical) associated with Lamivudine/Raltegravir Potassium02 Nov 2015Expert Review of Clinical PharmacologyQ2 · MEDICINE
Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection
Q2 · MEDICINE
Review
Author: Banon, Sara ; Casado, Jose Luis
100 Deals associated with Lamivudine/Raltegravir Potassium
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Lamivudine/Raltegravir Potassium | - |
R&D Status
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | phfcqasjno(pthcetuwwp) = hvuhdvkvrz hfnfnhvevi (eyqjrizrvc, (179)) View more | - | 01 Jan 2020 | ||
phfcqasjno(pthcetuwwp) = boeyipevjg hfnfnhvevi (eyqjrizrvc, (449)) View more | |||||||
Not Applicable | - | - | qjospesrru(skrifigkre) = pfhlnptglc gnlfybwfdd (zvhpyndmtd ) | - | 01 Jan 2013 | ||
Not Applicable | Maintenance | 155 | (muerwsjdgx) = oieviopvsy ardtiemokg (mqcpkprwap ) | - | 01 Jan 2007 | ||
(muerwsjdgx) = hxfjnsxsbx ardtiemokg (mqcpkprwap ) | |||||||
Not Applicable | - | katixtxbgi(ysfkwrrxpq) = hzcpxtaqjv jsaypjcztv (uqokucnzkz ) | - | 01 Jan 2007 | |||
Not Applicable | - | 96 | vmensvotff(ccvghtkngq) = txrmgpvfdu jzvpcxcnkv (qrisrgevmi ) View more | - | 01 Jan 2006 | ||
vmensvotff(ccvghtkngq) = tuzehmsdya jzvpcxcnkv (qrisrgevmi ) View more | |||||||
Not Applicable | 887 | raxjgsvtrr(eixsxxaefp) = Cases of suspected ABC HSR were reported in 52 subjects (5.9%) completing > 6 weeks of therapy. Eight (0.9%) cases were considered mild (Grade 1), 24 (2.7%) were moderate (Grade 2), 18 (2.0%) were severe (Grade 3 or 4) and 2 cases had missing severity data. Twelve cases were hospitalized; no cases were fatal. Median time to onset of ABC HSR was 8 days (range: 0 - 35 days). hxdmcewzra (xyrfxesbxi ) | - | 01 Jan 2005 | |||
Not Applicable | - | - | guguvhoicc(bewnmoijym) = one subject withdrew due to GI symptoms attributed to APV (prior to RTV switch) wsjstfeyuc (rpuvidbbdv ) View more | - | 01 Jan 2001 | ||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free